Phaseline

Targets › DNMT

DNMT (DNA): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

DNA methyltransferase that methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. (UniProt, P26358)

Open in Phaseline: the race on DNMT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)5-aza-4'-thio-2'-deoxycytidine (Aza-TdC)
DNA methyltransferase inhibitor; nucleoside analog that inhibits methylation-mediated gene
DNMTPhase 1NeoplasmsSep 2028

Conditions

Neoplasms (1)

Modalities

small molecule (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.